Clinical trial
The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of…
NCT00035321 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00035321 |
|---|---|
| Title | The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression |
| Official title | The Study of Olanzapine Plus Fluoxetine in Combination for Treatment-Resistant Depression Without Psychotic Features |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Major Depressive Disorder |
| Intervention type | Drug |
| Interventions | Olanzapine, Fluoxetine |
| Enrollment | 600 |
| Start date | Apr 1, 2002 |
| Completion | Jul 1, 2005 |
| First posted | May 3, 2002 |
| Last update posted | Jul 24, 2006 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: